Scienture (SCNX) vs. Its Rivals Head to Head Review

Scienture (NASDAQ:SCNX) is one of 248 publicly-traded companies in the “MED – DRUGS” industry, but how does it compare to its rivals? We will compare Scienture to similar businesses based on the strength of its valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.

Analyst Ratings

This is a breakdown of current ratings and price targets for Scienture and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1	0	0	0	1.00
Scienture Competitors	1951	3688	9724	395	2.54

As a group, “MED – DRUGS” companies have a potential upside of 74.67%. Given Scienture’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Scienture has less favorable growth aspects than its rivals.

Earnings & Valuation

This table compares Scienture and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Scienture	$128,202.00	$9.07 million	-0.27
Scienture Competitors	$30.36 billion	$57.83 million	-0.27

Scienture’s rivals have higher revenue and earnings than Scienture. Scienture is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Scienture and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scienture	-10,364.22%	-24.47%	-19.30%
Scienture Competitors	-19,383.46%	-93.67%	-16.11%

Risk & Volatility

Scienture has a beta of 3.04, meaning that its share price is 204% more volatile than the S&P 500. Comparatively, Scienture’s rivals have a beta of 1.28, meaning that their average share price is 28% more volatile than the S&P 500.

Insider & Institutional Ownership

5.7% of Scienture shares are owned by institutional investors. Comparatively, 43.8% of shares of all “MED – DRUGS” companies are owned by institutional investors. 21.4% of Scienture shares are owned by company insiders. Comparatively, 13.5% of shares of all “MED – DRUGS” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Scienture rivals beat Scienture on 8 of the 13 factors compared.

Scienture Company Profile

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.